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PV Isolation Using Bipolar/Unipolar RF Energy. Background: Electrical disconnection of the
pulmonary veins (PV) plays an important role in the ablation of paroxysmal atrial fibrillation (AF).
Antral ablation using a conventional steerable ablation catheter often is technically challenging and time
consuming.
Methods: Eighty-eight patients (mean age 58 ± 11 years) with symptomatic paroxysmal AF underwent
ablation with a circular mapping/ablation decapolar catheter (PVAC). Ablation was performed in the antral
region of the PVs with a power-modulated bipolar/unipolar radiofrequency (RF) generator using 8–10 W
delivered simultaneously through 2–10 electrodes, as selected by the operator. Seven-day Holter monitor
recordings were performed off antiarrhythmic drugs at 3-, 6-, and 12-month follow-up, and patients were
requested to visit the hospital in the event of ongoing palpitations. All follow-up patients were divided into
2 groups: Group 1 with a follow-up of less than 1 year and group 2 patients completing a 1-year follow-up.
Results: Overall, 338 of 339 targeted PVs (99%) were isolated with the PVAC with a mean of 24 ± 9 RF
applications per patient, a mean total procedure time of 125 ± 28 minutes, and a mean fluoroscopy time
of 21 ± 13 minutes. Freedom from AF off antiarrhythmic drugs was found in 82 and 79% of group 1 and
group 2 patients, respectively. No procedure-related complications were observed.
Conclusion: PV isolation by duty-cycled unipolar/bipolar RF ablation can be effectively and safely
performed with a circular, decapolar catheter. Twelve-month follow-up data compare favorably with early
postablation results, indicating stable effects over time. (J Cardiovasc Electrophysiol, Vol. 21, pp. 399-405,
April 2010)
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Introduction
Conventionally, pulmonary vein (PV) isolation for pa-
tients with atrial fibrillation (AF) is performed in a point-
by-point manner using a single-tip catheter delivering unipo-
lar radiofrequency (RF) energy. This technique requires a
high degree of operator skill and as a result the procedures
can be lengthy and may be associated with extensive radia-
tion exposure and procedural risks. In addition, creating reli-
able contiguous transmural lesions can be difficult with this
approach.
This study describes the acute electrophysiological effects
and follow-up results with a recently introduced technique for
PV isolation by antral ablation using an over-the-wire, mul-
tielectrode catheter system that delivers duty-cycled bipolar
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and unipolar RF energy simultaneously through up to 10
electrodes at relatively low power.1-5
Methods
Patients and Procedure
The study included 88 consecutive patients with drug re-
fractory paroxysmal AF undergoing catheter ablation in our
institution. All patients had symptomatic AF refractory to
at least 2 antiarrhythmic drugs and underwent catheter abla-
tion of AF after informed consent. They were screened with
transthoracic and transesophageal echocardiography before
ablation to rule out a significant reduction in left/right ven-
tricular systolic function, left atrial enlargement greater than
50 mm, or left atrial appendage thrombus.
All procedures were performed in the drug-free state, with
the exception of amiodarone, and with fentany/midazolam
to maintain conscious sedation. We used a recording system
(EP-WorkMate, St. Jude Medical, St. Paul, MN, USA/EP
Med Systems, West Berlin, NJ, USA) with filter settings of
100–500 Hz and maximum signal amplification for the PV
ablation catheter (PVAC) (AblationFrontiers, Inc., Carlsbad,
CA, USA). All other intracardiac bipolar signals were filtered
between 30 and 500 Hz with variable signal amplification.
No additional nonfluoroscopic mapping or navigation system
was used.
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Figure 1. PVAC mapping of a right superior PV in LAO (a) and RAO (b) projections. (a) The PVAC was decreased in its diameter to map PV potentials
within the vein. As a result, there is a visible overlap of the PVAC electrodes 1 and 2 with the electrodes 9 and 10. Clockwise rotation of the catheters
decreases the PVAC diameter. (b) Counterclockwise rotation of the PVAC increases the diameter of the catheter in the antral region of this vein where RF
ablation is performed. Note that electrodes 1 and 10 are now far apart. Further rotation of the PVAC after ablation is mandatory to create a continuous
lesion by overlapping the lesions.
A hexapolar electrode catheter was placed in the coro-
nary sinus (CS) for pacing and bipolar recordings. After
transseptal puncture, a fixed-curve long 10 Fr sheath (Fron-
tier Advance; AblationFrontiers, Inc.) was inserted into the
left atrium, and heparin was administered intravenously to
maintain an activated clotting time of 300–350 seconds. An-
giography was performed manually via the sheath to de-
lineate all PVs. The PVAC was then advanced through the
sheath into the left atrium to perform mapping and ablation of
the targeted PVs. Later in the procedure, another multipolar
steerable 6F catheter was placed into the left atrium using the
same access and used for differential pacing from several po-
sitions (left atrial appendage, posterior left atrial wall). This
catheter was also placed into the right atrium to pace from
different sites, if differentiation between right-sided PV po-
tentials and far-field atrial signals was necessary. At the end
of the procedure and after withdrawal of all catheters, an
echocardiogram was performed in the EP laboratory to rule
out pericardial effusion.
Pulmonary Vein Ablation Catheter
The PVAC is a 9 Fr, over-the-wire, circular, decapolar
mapping and ablation catheter with a 25-mm-diameter array
at the distal portion.1 The handle allows bidirectional de-
flection of the shaft and extension of the distal tip to form
a spiral configuration. The platinum electrodes (3 mm long,
1.5 mm outer diameter, 3 mm spacing) have a thermocou-
ple under the surface on the anterior side. Mapping of the
PVs is performed with 5 bipolar recordings through adjacent
electrode pairs. The diameter of the electrode array can be
effectively altered by engaging the shaft against anatomic
structures and rotating the catheter shaft. Thus, clockwise
rotation decreases the diameter to allow more distal posi-
tions inside the PV, whereas counterclockwise rotation in-
creases the diameter of the array, facilitating antral ablation
around larger veins (Fig. 1). The PVAC is positioned in the
antral region of the targeted PV over a 0.032′′ guide wire,
which is selectively placed into different side branches of the
PV to improve the tissue-electrode interface around the PV
circumference.
GENius Multichannel RF Generator
The GENius multichannel RF generator (Frontier Ad-
vance, AblationFrontiers, Inc.) was used for all ablation pro-
cedures. It is capable of independently delivering duty-cycled
RF energy to a maximum of 12 electrodes simultaneously.
AC power can be delivered in various combinations of unipo-
lar and/or bipolar current. The unipolar energy consists of
current flowing from the catheter electrode to the dispersive
electrodes on the patient’s back, and the bipolar energy con-
sists of current flow between adjacent pairs of electrodes of
the catheter array. Because electrodes 1 and 10 are far apart,
the current flow between them is negligible. The generator
offers 5 different preset energy settings: unipolar, bipolar,
and different ratios of bipolar/unipolar energy in a 4:1, 2:1,
and 1:1 fashion, respectively. Electrode pairs can be acti-
vated or deactivated for RF ablation selectively, depending
on electrogram interpretation and tissue contact. During RF
applications, energy delivery to individual electrodes is tem-
perature controlled by a software algorithm that modulates
power to reach the user-defined target temperature. It limits
the power to a maximum of 8 W per electrode in the 4:1-
ablation-mode and to a 10 W maximum in all other settings.
Thus lesion depth and overlap between electrodes are con-
trolled by varying the energy settings on the generator, with
depth achievable up to 7 mm in the unipolar mode.5,6
Mapping and Ablation Protocol
The PVAC was deployed in the left atrium over a 0.032′′
guide wire inside the PV and then advanced until it was in
close contact with the antral region proximal to the ostium.
Contact was assessed by electrogram interpretation, oper-
ator sensation, and temperature during ablation. Stimulation
was performed from different left atrial regions (distal CS
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Figure 2. Intracardiac signals from PVAC in the antral region of a LSPV. Differential pacing from the distal coronary sinus (left) and LAA (right) to
distinguish delayed antral conduction as a result of ablation from residual PV potentials. Detection of late and fragmented local electrograms from PVAC
pair 1 and 2, when pacing is performed from the distal CS. Pacing from LAA clearly identifies these late signals in pair 1 and 2 as residual delayed PV
potentials, whereas the split signal in pair 3 is now captured and advanced by pacing.
and left atrial appendage, posterior left atrium) and right
atrial regions (right atrial appendage, posterior right atrial
wall), for the detection of PV-potentials originating from the
left- and right-sided PVs, respectively (Fig. 2). If no PV po-
tentials were detected with the PVAC in the antral region,
the catheter was further advanced into the PV ostium or in-
side the vein and the stimulation maneuvers were repeated.
All veins showing PV-potentials spontaneously or as a re-
sult of pacing were targeted for antral ablation to achieve
PV isolation. An optimal position for ablation was based on
electrograms, with the goal of ablating local antral potentials
of high amplitude on as many electrodes as possible for each
application until all local potentials were abolished. Care was
taken to avoid energy application inside the PVs. Common
ostia were isolated by inserting the guide wire into the dif-
ferent side branches and ablating subsequent segments of the
targeted veins.
Ablation in the antral region was always initiated in a
4:1 bipolar/unipolar ratio with all electrodes showing local
electrical activity being activated to achieve contiguous trans-
mural antral lesions, as far as possible, with a single catheter
position. Later in the ablation procedure, RF applications in
a 2:1 or even 1:1 mode were applied if PV isolation could not
be obtained with the 4:1 setting. These applications were lim-
ited to individual electrodes showing local electrical activity
to minimize collateral injury. Each energy application lasted
60 seconds and temperature was limited to 60◦C for each
electrode in the selected pairs. This approach was repeated
for all targeted PVs until electrical disconnection of all veins
was demonstrated. For mapping, the PVAC was repeatedly
advanced into the PV ostium for mapping and stimulation
as suggested by Iwasa et al.7 or inside the vein to show the
elimination of all PV potentials or their electrical dissociation
from the atrial activity (Fig. 3). PV isolation was defined as
entrance block in all patients. If there were residual potentials
near the PV ostium or inside the vein, differential pacing from
different regions of the left and right atrium was performed to
differentiate residual PV conduction from atrial far-field sig-
nals. In case of confirmed PV potentials, additional selective
RF applications in the antral region of this vein were per-
formed until isolation was complete (Fig. 4). If AF persisted
during the ablation procedure and made the interpretation of
the local electrograms obtained from the PVAC difficult, si-
nus rhythm was restored by external electrical cardioversion.
Postablation Management
At the completion of the procedure, anticoagulation with
low molecular weight heparin was applied 2 hours after
hemostasis was achieved and continued until the target INR
(2.5) was reached when warfarin was administered. Anti-
coagulation with warfarin was continued in all patients for
3 months, and the patients were discharged from the hospi-
tal 2 days after the procedure. The last 12 patients treated
with the PVAC underwent endoscopy of the esophagus by a
gastroenterologist 24 hours after the ablation procedure.
Follow-Up
Patients were seen 3, 6, and 12 months after the ablation
procedure in an outpatient clinic. Antiarrhythmic drug ther-
apy was used in patients with early and recurrent episodes
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Figure 3. Bipolar electrograms recorded
from the PVAC (1–10) placed within a
left superior PV. Shown is the onset of a
very rapid electrical activity of 160 ms
within this vein with no conduction to
the atria, since lead II and intracardiac
recordings in the coronary sinus (CS) and
right atrium (RA) demonstrate a disso-
ciated regular slow atrial rhythm. This
was recorded after antral ablation with
the PVAC.
of symptomatic AF and discontinued after a blanking period
of 3 months at least 3 days before the first follow-up evalua-
tion. Therapy with amiodarone was discontinued at the time
of ablation. Patients were requested to visit the hospital in
the event of ongoing palpitations. Seven-day Holter monitor
recordings were performed off antiarrhythmic drug therapy
at each follow-up interval, starting 3 months after the initial
procedure. Freedom from AF was defined as the absence
of AF /flutter/tachycardia lasting >30 seconds after a single
ablation procedure, in the absence of antiarrhythmic drug
therapy.
Group 1 consists of all patients with a follow-up pe-
riod of less than 1 year, while group 2 includes pa-
tients completing a 12-month follow-up. All patients who
Figure 4. Antral PVAC mapping with 5
bipoles (1–5) of a left inferior PV before
(left) and after ablation (right). Stimula-
tion is performed from the LAA demon-
strating fragmentation of the antral elec-
trograms in all pairs as a result of previ-
ous energy applications. PV potentials are
detected at pairs 1 and 5. Energy deliv-
ery for 60 seconds via the corresponding
PVAC bipoles 1 and 5 with a 2:1 bipo-
lar/unipolar ratio resulted in elimination
of the PV potentials.
required a redo procedure within the follow-up period
were classified as a primary failure of the initial ablation
procedure.
At 6-month follow-up MRI was performed in 18 patients
because AF ablation near the PVs is known to be a risk factor
for PV stenosis, which was defined as PV diameter reduction
of 30% or more.
Results
Table 1 shows the characteristics of the study group. The
mean left ventricular ejection fraction was 61 ± 6%, and the
mean left atrial diameter was 44 ± 4 mm. The percentage of
patients with lone AF was 66%.
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TABLE 1
Patient Characteristics
No. of Patients 88
Age (years) 58 ± 11 (30–73)
Male/female 55/33
Left atrial diameter (mm) 44 ± 4 (35–49)
No. of antiarrhythmic drugs 1.8 ± 1.3 (1–4)
Amiodarone 8
Hypertension 29
Coronary heart disease 11
No structural heart disease 58
Left ventricular ejection fraction (%) 61 ± 6 (53–77)
Acute Results
In the 88 patients, 354 PVs were detected by angiography,
including 13 patients with a left common trunk. PVAC could
be steered to 353/354 PVs (99%) using a nonsteerable sheath.
PV potentials were observed in 339/353 PVs (96%) either
spontaneously or as a result of pacing maneuvers and were
therefore targeted for antral ablation. The other veins were
not treated with ablation in this study.
The detailed results of a single ablation procedure with
the PVAC are summarized in Table 2. Complete PV isolation
was achieved in all but 1 left inferior PV (99%) with a mean
of 24 ± 9 energy applications per patient.
Most of the energy applications (82%) were administered
with the patients in sinus rhythm. AF for >60 s was induced
during 4% of all applications of energy in the antral regions
of the PVs. A spontaneous or ablation-induced episode of
AF terminated in 11% of all patients during ablation with
the PVAC. The mean number of transthoracic cardioversions
was 1.2 ± 1.1 per patient (range 0–4).
The mean procedure time was 125 ± 28 minutes (range
59–211 minutes); the mean fluoroscopy time for PV isolation
with the PVAC was 21 ± 13 minutes (range 14–46 minutes).
There were no acute or late procedure-related complications.
Endoscopy of the Esophagus
All 12 patients undergoing endoscopy of the esophagus
24 h after the ablation procedure showed normal esophageal
mucosa.
TABLE 2




PVs reached with PVAC 353/354 (99%)
Targeted veins showing PV potentials 339/353 (96%)
Successful PV isolation with PVAC 338/339 (99%)
Mean no. of RF applications 24 ± 9 [10–46]
Mean no. of external cardioversions 1.2 ± 1.1 [0–4]
Procedure time (minute) 125 ± 28 [59–211]
Fluoroscopy time (minute) 21 ± 13 [14–46]
Complications 0/88
PV = pulmonary vein.
TABLE 3
Follow-Up Results
Group 1 Group 2
>3 and <12 Months ≥12 Months
n = 73 n = 24
Freedom from AF 60 (82.2%) 19 (79.2%)
AF/failure 13 5
Redo procedures 6 (8.2%) 1 (4.2%)
No intervention 7 2
Follow-Up Results
In group 1, recurrence of AF, detected by Holter monitor-
ing and/or by 12 lead ECG because of symptomatic ongoing
palpitations, was observed in 13 of 73 patients within a mean
follow-up period of 4.8 ± 1.5 months, while freedom of
AF was found in 82.2% of them. Seven patients decided to
have a redo procedure, while 7 patients declined because the
episodes were asymptomatic (n = 3), brief (n = 4), and/or
infrequent (n = 3).
In group 2, 3 of the 24 patients still had AF episodes at
12 months of follow-up. Two other patients in this group
had already undergone a redo procedure, while 19 patients
were in sinus rhythm with freedom from AF (79.2%). A sec-
ond ablation procedure was performed in 1 patient who was
known to have recurrent AF by earlier follow-up evaluation
(Table 3).
There were no episodes of left atrial tachycardia or left
atrial flutter detected in any of the patients during follow-
up. In all patients undergoing a second procedure, we found
varying patterns of PV reconnection(s) to the left atrium.
Angiography of the PVs showed no evidence of PV stenosis
in these patients.
In the subgroup of patients who completed all follow-up
visits (n = 24), freedom from AF was observed in 79% at
3-month, 83% at 6-month, and 79% at 12-month follow-up,
respectively.
MR Imaging
None of the 18 patients with MRI at 6-month follow-up
had any evidence of hemodynamically relevant PV stenosis.
Discussion
In this study, a cohort of patients with paroxysmal AF was
treated with a decapolar spiral catheter system that delivers
RF energy in a bipolar/unipolar fashion. It can be used for
both mapping and ablation and eliminates the need for 3-D
imaging tools or remote navigation.
Acute Efficacy
Current approaches utilized for PV mapping and abla-
tion require multielectrode mapping catheters or sophisti-
cated mapping systems and result in approximately 65–85%
long-term success.8-11 Limitations of this approach include
prolonged learning curves, the need for more than 1 catheter
in the left atrium, prolonged procedure times, and significant
risk of complications. Alternatively, a single conventional
catheter in conjunction with an electroanatomical mapping
system has been successfully used for circular and linear
point-by-point RF delivery in patients with AF.10,12 With
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our approach, 99% of all targeted PVs were isolated with
one mapping/ablation catheter without the use of a steerable
sheath in a series of 88 consecutive patients.
Our acute success rate compares favorably with the re-
sults presented by other investigators. In a study by Boersma
et al., 100% of PVs were successfully isolated using the
same system in a series of 98 patients.1 Using conventional-
tip catheters, Cheema et al. reported a 75% success rate,13,14
while Hocini et al. and Verma et al. report 100% success
rates with the isolation of PVs.15-17
Various investigational devices utilizing ultrasound, laser,
or cryoenergy have been evaluated to simplify PV electri-
cal isolation procedures.18-21 These devices are not designed
for mapping, and an additional catheter is required to eval-
uate for PV isolation. A mesh catheter can overcome these
limitations. This catheter, which is placed in the region of
the PV antrum, is able to deliver RF energy in a pulsed,
temperature-control mode over selected electrodes and map
the corresponding electrical activity in the region of the PV
ostium. Initial clinical experience with the mesh catheter was
recently reported by Steinwender et al.22 These investigators
reported a 97% success rate for PV isolation of all targeted
veins in a group of 26 patients, with a mean fluoroscopy
and procedure time of 34.6 ± 10.0 and 187 ± 36 minutes,
respectively.22
Ablation Strategy and Follow-Up Results
Our ablation strategy differs from the approach of
Boersma et al., who used the same ablation system.1 Only
those veins with spontaneous or stimulation-induced PV po-
tentials were targeted for antral ablation in our series. This
resulted in RF ablation of 96% of all PVs. Other investigators
have limited PV isolation to potentially arrhythmogenic PVs
as well.22 Despite this difference, the acute results and the
clinical course during follow-up were very similar: after 6
months, 83% of all patients in the study of Boersma were
free from AF,1 while 82 and 79% of our patients off antiar-
rhythmic drugs did not show AF after a mean follow-up of 5
months and 1 year, respectively.
This is the first study with the PVAC presenting 1-year
clinical results in a subgroup of patients after PV isolation.
We found a slight decrease in freedom from AF at 12-month
follow-up, with 79% of patients in sinus rhythm. It seems that
in most patients, the early results after ablation remain stable
over time. Comparable results were seen when only the first
24 patients who completed all follow-up visits are analyzed.
Other investigators have published similar data, reporting
freedom from AF in 56 and 92% of patients, depending on
the ablation strategy and intensity of follow-up.8,12,13,23
Procedure Times
The mean total procedure time from femoral vein access
to complete catheter withdrawal was 125 ± 28 minutes, with
a fluoroscopy time of 21 ± 13 minutes. While the fluo-
roscopy time differs only slightly from that of Boersma et al.
(18 ± 8 minutes), a significantly shorter mean procedure time
(84 ± 29 minutes) was reported by this group.1 The reasons
for this difference might be the PV mapping maneuvers used
in our study: to clearly differentiate between residual PV con-
duction from far-field signals in the region of the PV antrum
or PV ostium, we paced in the CS, LAA, posterior LA, and
different sites in the right atrium.
With conventional single-tip catheters, a wide range of
procedural and fluoroscopy times have been reported for
complete PV isolation: 70 (Hocini et al.)15 to 256 (Karch
et al.)24 minutes procedure time and 18–72 minutes fluo-
roscopy time, respectively. Many of these studies used an
electroanatomical 3-D mapping system for guiding the ab-
lation procedure. Using alternative energy sources such as
cryoenergy resulted in a total procedure time of 211 ± 108
minutes with a mean fluoroscopy time of 52 ± 36 minutes.25
Significantly, shorter procedure and fluoroscopy times were
reported with the mesh catheter in 26 patients for PV isola-
tion.22,26
The PVAC isolation technique compares favorably to con-
ventional and investigational techniques, with significantly
shorter procedure and fluoroscopy times, and with no re-
quirement for 3-D mapping systems.
Safety
There were no procedure-related complications in this
study. In the studies by Boersma et al. and Fredersdorf et al.,
no complications occurred in series of 98 and 21 patients,
using the same technology.1,27 A worldwide survey on the
methods and safety of conventional catheter ablation for AF
published in 2005 reported an incidence of major complica-
tions of 6%.23
Endoscopy of the esophagus performed 24 hours after ab-
lation revealed esophageal wall injuries in 47% of patients
undergoing PV antrum isolation with conventional 8 mm and
irrigated tip electrodes.28 In contrast, in the last 12 patients
in this study, there were no esophageal lesions in any pa-
tient. By using alternating bipolar/unipolar RF energy with a
power maximum of 10 W, the risk of collateral damage to the
surrounding structures (phrenic nerve, esophagus)28,29 may
be minimized.
We found no evidence for hemodynamically relevant PV
stenosis with MR imaging in 18 patients at 6-months follow-
up and/or angiographically in 7 patients with a redo pro-
cedure. Similar data were presented by Boersma et al. and
Fredersdorf et al. in 19 and 21 patients, respectively.1,27
Limitations
Although an ablation efficacy of 82 and 79% after a mean
follow-up of 5 and 12 months is an encouraging result, longer
follow-up periods with more patients are necessary, since the
effect of catheter ablation has been shown to decline over
time in some patients.30 The number of patients reaching 1-
year follow-up is still too small for a final statement on the
clinical efficacy of the method described. No data dealing
with the potential issue of PV stenosis31 are available for all
patients in this study. However, in other studies using the
same device for antral ablation, there was no evidence of PV
stenosis at MRI follow-up or angiographically.1,27
Conclusions
PV isolation with the multiarray PVAC system in conjunc-
tion with low-power phased RF energy appears to be safe and
feasible, with a promising clinical efficacy that appears sta-
ble over time. Compared to other ablation systems in clinical
and investigational use, the procedure and fluoroscopy times
appear to be relatively shorter.
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